Collector
Intellia is seeking FDA approval for what could be the first in vivo CRISPR gene editing therapy | Collector
Intellia is seeking FDA approval for what could be the first in vivo CRISPR gene editing therapy
Quartz

Intellia is seeking FDA approval for what could be the first in vivo CRISPR gene editing therapy

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for a potential 2027 launch

Go to News Site